Potential cure for sickle cell disease raises few concerns for FDA panel
A panel of the Food and Drug Administration’s outside advisers voiced few concerns Tuesday during a daylong meeting wrestling with any potential risks posed by a new therapy that could cure sickle cell disease using a gene editing technology called CRISPR. If approved by the FDA, the infusion called exa-cel, from Vertex Pharmaceuticals, could be
Read More